Search Results | Blood | American Society of Hematology

1-20 of 130

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost

Ayrton Bangolo, Samir Oza, Ronit Slotky, Aimee Chappell, David Siegel, Harsh Parmar, Noa Biran, David H. Vesole, Pooja Phull

Blood (2022) 140 (Supplement 1): 10041–10042.

DOI: https://doi.org/10.1182/blood-2022-171012

Published: 2022

Journal Articles

The Clinical Characteristics and Epidemiology of Extramedullary Multiple Myeloma over the Past Two Decades

Blood (2022) 140 (Supplement 1): 12521–12522.

DOI: https://doi.org/10.1182/blood-2022-170783

Published: 2022

Journal Articles

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2022) 140 (Supplement 1): 7264–7266.

DOI: https://doi.org/10.1182/blood-2022-157525

Published: 2022

Journal Articles

Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Samir Oza, Ronit Slotky, Pranay Vissa, Pooja Phull, Sukhdeep Kaur, Hyung C. Suh, Michele L. Donato, Scott D. Rowley, Noa Biran, David H. Vesole, David Siegel, Harsh Parmar

Blood (2022) 140 (Supplement 1): 10441–10442.

DOI: https://doi.org/10.1182/blood-2022-171098

Published: 2022

Journal Articles

Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes

Laurent Garderet, Mohammad Al Hariri, Joanna Wasielica-Poslednik, Markus Munder, Kitti Kormányos, Camila Peña, Alessandro Gozzetti, Xiang Zhou, Anna Waszczuk-Gajda, Laura Rosinol, Gabor Mikala, Mateusz Krzystanski, Walter Lisch, David H. Vesole, Nora Szentmáry, Artur Jurczyszyn

Blood (2021) 138 (Supplement 1): 2695.

DOI: https://doi.org/10.1182/blood-2021-151460

Published: 2021

Journal Articles

Impact of Treating Facility on Overall Survival and Treatment in Multiple Myeloma (MM) Using National Cancer Database (NCDB)

Kimberley Doucette, Allison Taylor, Bryan Chan, Xiaoyang Ma, Jaeil Ahn, David H. Vesole, Catherine Lai

Blood (2021) 138 (Supplement 1): 2996.

DOI: https://doi.org/10.1182/blood-2021-153021

Published: 2021

Journal Articles

Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed

Sarvarinder K Gill, Rashmi Unawane, Shuqi Wang, Adolfo Aleman, Michelle Serna, Fideliza Perez-Manon, Gina Rivieccio, David S. Siegel, David H. Vesole, Harsh Parmar, Jaeil Ahn, Noa Biran

Blood (2021) 138 (Supplement 1): 4742.

DOI: https://doi.org/10.1182/blood-2021-153556

Published: 2021

Journal Articles

Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases

Hyung C. Suh, MDPhD, Scott D. Rowley, MD, Sukhdeep Kaur, MD, Brittany Lukasik, Phyllis McKiernan, Michele Boonstra, APN, Milissa Baker, MSN, ANP, Mary E Dilorenzo, APN, Alan Skarbnik, MD, Themba Nyirenda, PhD, David H. Vesole, MD PhD, Michele L. Donato, MD

Blood (2020) 136 (Supplement 1): 9.

DOI: https://doi.org/10.1182/blood-2020-142272

Published: 2020

Journal Articles

Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

Ola Landgren, MD PhD, Melissa Alsina, MD, Noa Biran, MD, David H. Vesole, MD PhD, Paul K. Wallace, MS, PhD, Belle Fang, Gregory Arnold, Amy Kimball, MD PhD, David S. Siegel, MD PhD

Blood (2020) 136 (Supplement 1): 28.

DOI: https://doi.org/10.1182/blood-2020-133803

Published: 2020

Journal Articles

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Pashna N. Munshi, MD, Parameswaran Hari, MBBS, MD, David H. Vesole, MD PhD, Artur Jurczyszyn, MD, Jan Zaucha, MD PhD, Omar Davila, Shaji K. Kumar, MD, Nina D. Shah, MD, Muzaffar H. Qazilbash, MD, Anita D'Souza, MDMS

Blood (2019) 134 (Supplement_1): 782.

DOI: https://doi.org/10.1182/blood-2019-124804

Published: 2019

Journal Articles

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Meena Bansal, DO, David S. Siegel, Jaeil Ahn, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Andrew L. Pecora, MD, Elli Gourna Paleoudis, PhD, Scott D. Rowley, MD, Michele L. Donato, MD, Robert Korngold, PhD, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 1911.

DOI: https://doi.org/10.1182/blood-2019-125155

Published: 2019

Journal Articles

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Patrick Hagen, MD, Anita D'Souza, MDMS, Parameswaran Hari, MBBS, MD, Omar Davila, Mei-Jie Zhang, David H. Vesole, MD PhD, Scott E. Smith, MD PhD, Tulio E Rodriguez, MD, Patrick J. Stiff, MD

Blood (2019) 134 (Supplement_1): 2023.

DOI: https://doi.org/10.1182/blood-2019-124188

Published: 2019

Journal Articles

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Sudarsan Kollimuttathuliam, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Stuart L. Goldberg, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 4576.

DOI: https://doi.org/10.1182/blood-2019-132052

Published: 2019

Journal Articles

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Marshall McKenna, MD, Rena Feinman, PhD, Jaeil Ahn, PhD, Shuqi Wang, MSc, Elli Gourna Paleoudis, PhD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Jun Chih Wang, MD, Abdul Rehman, MD, Giselle Alexandra Suero-Abreu, MD PhD, Phyllis McKiernan, Michele L. Donato, MD, Scott D. Rowley, MD, David S. Siegel, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 5510.

DOI: https://doi.org/10.1182/blood-2019-132134

Published: 2019

Journal Articles

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Marshall McKenna, MD, Phyllis McKiernan, David S. Siegel, Scott D. Rowley, MD, Noa Biran, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, Themba Nyirenda, PhD, Andrew L. Pecora, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2019) 134 (Supplement_1): 3316.

DOI: https://doi.org/10.1182/blood-2019-132114

Published: 2019

Journal Articles

Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma

Nikhita Gadi, MDMSc, Linda Schmidt, RN, Jaeil Ahn, PhD, Tianmin Wu, MS, Scott D. Rowley, MD, Elli Gourna Paleoudis, PhD, Michele L. Donato, MD, David H. Vesole, MD PhD, Stuart L. Goldberg, MD, David S. Siegel, Noa Biran, MD

Blood (2019) 134 (Supplement_1): 3141.

DOI: https://doi.org/10.1182/blood-2019-129504

Published: 2019

Journal Articles

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Sarah S. Makhani, BA, Ronit Reich-Slotky, PhD, Pashna N. Munshi, MD, Noa Biran, MD, Michele L. Donato, MD, Stuart L. Goldberg, MD, Andrew L. Pecora, MD, David S. Siegel, David H. Vesole, MD PhD, Scott D. Rowley, MD

Blood (2019) 134 (Supplement_1): 4475.

DOI: https://doi.org/10.1182/blood-2019-122111

Published: 2019

Journal Articles

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Ning Dong, MD, David S Siegel, MD PhD, Phyllis McKiernan, Noa Biran, MD, Alan P Skarbnik, MD, David H. Vesole, MD PhD, Andrew L. Pecora, MD, Scott D. Rowley, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 4554.

DOI: https://doi.org/10.1182/blood-2018-99-117498

Published: 2018

Journal Articles

Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, David S Siegel, MD PhD, Noa Biran, MD, David H. Vesole, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Phyllis McKiernan, Melissa Baker, MSN, ANP, Michele L. Donato, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 4604.

DOI: https://doi.org/10.1182/blood-2018-99-120103

Published: 2018

Journal Articles

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Phyllis McKiernan, David S Siegel, MD PhD, David H. Vesole, MD PhD, Tracy Andrews, MSc, Noa Biran, MD, Scott D. Rowley, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Jacquelyn Callahan, RN, Andrea Ortega, RN, Mariefel Vendivil, RN, Supreet Kaur, MD, Marshall McKenna, MD, Michele L. Donato, MD

Blood (2018) 132 (Supplement 1): 1020.

DOI: https://doi.org/10.1182/blood-2018-99-117313

Published: 2018

2 3 4 5

NARROW

Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost

The Clinical Characteristics and Epidemiology of Extramedullary Multiple Myeloma over the Past Two Decades

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes

Impact of Treating Facility on Overall Survival and Treatment in Multiple Myeloma (MM) Using National Cancer Database (NCDB)

Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed

Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases

Assessment of Minimal Residual Disease in a Phase 1b Study of Once-Weekly Carfilzomib Combined with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma

Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Long Term Follow up of a Novel Conditioning Regimen

Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients

Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation

Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma

Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)

Comparison of Peripheral Blood Stem Cell Mobilization for Multiple Myeloma Patients over 70 Years of Age with Younger Patients

Evaluation of T Cell and Monocyte Immune Subsets in the Stem Cell Product of Patients Developing Engraftment Syndrome Following Autologous Stem Cell Transplantation for Multiple Myeloma and Lymphoma

Prospective Analysis of Bortezomib, Fludarabine and Melphalan As Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation for Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only